Today’s Short Interest Alert: Time to Reconsider Durect Corporation (NASDAQ:DRRX) After More Short Sellers?

December 1, 2016 - By Louis Casey   ·   0 Comments

Today's Short Interest Alert: Time to Reconsider Durect Corporation (NASDAQ:DRRX) After More Short Sellers?

The stock of Durect Corporation (NASDAQ:DRRX) registered an increase of 21.52% in short interest. DRRX’s total short interest was 4.20 million shares in December as published by FINRA. Its up 21.52% from 3.45 million shares, reported previously. With 400,600 shares average volume, it will take short sellers 11 days to cover their DRRX’s short positions. The short interest to Durect Corporation’s float is 3.37%. About 105,778 shares traded hands. DURECT Corporation (NASDAQ:DRRX) has declined 6.43% since April 28, 2016 and is downtrending. It has underperformed by 12.35% the S&P500.

Durect Corporation is a biopharmaceutical firm with research and development programs. The company has a market cap of $177.35 million. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. It currently has negative earnings. The Company’s other product candidates include POSIMIR , REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR opioid (hydromorphone) and SABER ophthalmic.

Insitutional Activity: The institutional sentiment decreased to 1.2 in Q2 2016. Its down 0.50, from 1.7 in 2016Q1. The ratio dived, as 8 funds sold all DURECT Corporation shares owned while 19 reduced positions. 9 funds bought stakes while 37 increased positions. They now own 67.65 million shares or 18.85% more from 56.92 million shares in 2016Q1.
Morgan Stanley last reported 0% of its portfolio in the stock. Commonwealth Equity Incorporated has 0% invested in the company for 15,500 shares. State Board Of Administration Of Florida Retirement Systems accumulated 0% or 64,381 shares. Moreover, Bank Of America Corp De has 0% invested in DURECT Corporation (NASDAQ:DRRX) for 50,641 shares. Moreover, Ameriprise has 0% invested in DURECT Corporation (NASDAQ:DRRX) for 251,484 shares. Stifel Fincl holds 11,335 shares or 0% of its portfolio. Schwab Charles Inv, a California-based fund reported 177,776 shares. Zazove Assoc Ltd Liability accumulated 125,841 shares or 0.01% of the stock. Credit Suisse Ag holds 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 80,057 shares. Ingalls And Snyder Limited Company, a New York-based fund reported 1.80 million shares. Tfs Capital Ltd Liability Corporation accumulated 0.08% or 347,590 shares. Blackrock Institutional Tru Na has 4.10M shares for 0% of their US portfolio. Tower Cap Ltd Liability (Trc) owns 1,262 shares or 0% of their US portfolio. The Massachusetts-based Geode Lc has invested 0% in DURECT Corporation (NASDAQ:DRRX). Regis Management Ltd Company, a California-based fund reported 134,250 shares.

Insider Transactions: Since September 26, 2016, the stock had 2 buys, and 0 sales for $2.99 million net activity. 21 APRIL FUND – LTD. had bought 2.50M shares worth $2.88M. On Thursday, November 3 First Eagle Investment Management – LLC bought $110,298 worth of the stock or 95,000 shares.

DRRX Company Profile

Durect Corporation, incorporated on February 6, 1998, is a biopharmaceutical firm with research and development programs. The Company’s research and development programs fall into two categories: new chemical entities derived from its Epigenomic Regulator Program, in which the Company attempts to discover and develop molecules, which have not previously been approved and marketed as therapeutics, and Drug Delivery Programs, in which the Company applies its formulation expertise and technologies to active pharmaceutical ingredients whose safety and efficacy have previously been established but which the Company focuses to improve through a new formulation. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR opioid (hydromorphone) and SABER ophthalmic.

More notable recent DURECT Corporation (NASDAQ:DRRX) news were published by: Fool.com which released: “Here’s Why DURECT Corporation Is Tanking Today” on September 26, 2016, also Seekingalpha.com with their article: “Durect Corporation Seeking More Collaborations” published on November 15, 2016, Prnewswire.com published: “DURECT Corporation Announces Third Quarter 2016 Financial Results and Update …” on October 31, 2016. More interesting news about DURECT Corporation (NASDAQ:DRRX) were released by: Prnewswire.com and their article: “DURECT Corporation Announces Second Quarter 2016 Financial Results and Update …” published on August 01, 2016 as well as Prnewswire.com‘s news article titled: “DURECT Corporation Announces First Quarter 2016 Financial Results and Update …” with publication date: May 05, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>